Quick Answer
iRhythm Holdings, Inc. reported Research And Development Expense of $60.24 million for the year ending 2023.
- iRhythm Holdings, Inc. showed an increase of +29.3% in Research And Development Expense from 2022 to 2023.
- This data is from iRhythm Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on February 22, 2024.
- XBRL data for this metric is available from 2014 to 2023 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2015: $1.65 million | Q1 2016: $1.55 million | Q2 2016: $1.67 million | Q3 2016: $1.64 million | Q1 2017: $2.62 million | Q2 2017: $2.78 million | Q3 2017: $3.79 million | Q1 2018: $4.04 million | Q2 2018: $4.65 million | Q3 2018: $5.09 million | Q1 2019: $6.70 million | Q2 2019: $7.83 million | Q3 2019: $13.50 million | Q1 2020: $8.42 million | Q2 2020: $12.54 million | Q3 2020: $8.77 million | Q1 2021: $8.51 million | Q2 2021: $9.61 million | Q3 2021: $8.69 million | Q1 2022: $10.54 million | Q2 2022: $11.95 million | Q3 2022: $11.45 million | Q1 2023: $14.84 million | Q2 2023: $13.68 million | Q3 2023: $16.31 million | Q1 2024: $16.99 million | Q2 2024: $19.69 million.
- Over the full 10 years of available data (2014 to 2023), iRhythm Holdings, Inc.'s Research And Development Expense has grown by 957.3%.
- Historical annual values: Fiscal year 2023: $60.24 million | Fiscal year 2022: $46.61 million | Fiscal year 2021: $38.67 million | Fiscal year 2020: $41.33 million | Fiscal year 2019: $37.30 million | Fiscal year 2018: $20.86 million | Fiscal year 2017: $13.27 million | Fiscal year 2016: $7.15 million | Fiscal year 2015: $6.35 million | Fiscal year 2014: $5.70 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: